Profile Response Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile KIT exon9
Therapy Imatinib
Indication/Tumor Type gastrointestinal stromal tumor
Response Type sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
KIT exon9 gastrointestinal stromal tumor sensitive Imatinib Case Reports/Case Series Actionable In a Phase III trial (CALGB 150105), Gleevec (imatinib) treatment resulted in a higher objective response rate at a dose of 800mg (n=18) compared to 400mg (n=14) (67% vs 17%, p=0.02) in patients with advanced gastrointestinal stromal tumor harboring KIT exon 9 mutations (PMID: 18955451). 18955451
KIT exon9 gastrointestinal stromal tumor sensitive Imatinib Guideline Actionable Gleevec (imatinib) is included in guidelines for gastrointestinal stromal tumor (GIST) patients harboring sensitizing mutations, such as KIT exon 9 mutations, as adjuvant therapy for patients with localized disease and as first-line therapy for patients with locally advanced, unresectable, or metastatic disease (PMID: 34560242; ESMO.org). 34560242 detail...
KIT exon9 gastrointestinal stromal tumor sensitive Imatinib Guideline Actionable Gleevec (imatinib) is included in guidelines for patients with gastrointestinal stromal tumor (GIST) harboring KIT exon 9 mutations (NCCN.org). detail...
KIT exon9 gastrointestinal stromal tumor sensitive Imatinib Clinical Study - Meta-analysis Actionable In a meta-analysis of two phase III trials (MetaGIST), high-dose Gleevec (imatinib) treatment in patients with gastrointestinal stromal tumors harboring KIT exon 9 mutations resulted in a similar overall survival (p=0.15) but an increased progression-free survival (HR=0.58, p=0.017) and increased best overall response rate (47% vs 21%, p=0.0037) compared to low-dose Gleevec (imatinib) treatment (PMID: 20124181; NCT00685828, NCT00009906). 20124181
PubMed Id Reference Title Details
NCCN.org Full reference...
ESMO Clinical Practice Guidelines Full reference...
(34560242) Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Full reference...
(18955451) Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. Full reference...
(20124181) Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. Full reference...